Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2017-03-08 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Medical to present at The Oppenheimer 27th Annual Healthcare Conference
Regulatory Filings Classification · 90% confidence The document is a short press release dated March 8, 2017, announcing that Hansa Medical will present at 'The Oppenheimer 27th Annual Healthcare Conference' on March 21. It provides details about the CEO's presentation time and includes a link to a live audio webcast. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing about share transactions or dividends. It is an announcement regarding the company's participation in an investor event, which aligns best with an Investor Presentation (IP) announcement or, more generally, a Regulatory Filing (RNS) if a specific investor event announcement code isn't available. Since the core purpose is to inform investors about an upcoming presentation where company strategy/financials might be discussed, 'Investor Presentation' (IP) is a strong candidate, although it's an announcement *about* a presentation, not the presentation itself. Given the options, and the nature of informing investors about an upcoming event where they will present, 'IP' is the most contextually relevant category for the subject matter, even if it's a short announcement. However, following the 'MENU VS MEAL' rule, if this were the actual presentation slides, it would be IP. As it is a short announcement about the presentation, it fits well under a general Regulatory Filing (RNS) or potentially a specific Investor Relations communication. Since there is no specific code for 'Investor Event Announcement', and it is a formal communication about investor engagement, I will classify it as an Investor Presentation (IP) as it directly relates to the content that will be presented, or RNS as a general announcement. Given the content focuses entirely on an upcoming investor conference presentation, IP is the most specific fit for the *topic* being communicated, despite the short length suggesting RPA/RNS. I will lean towards RNS as the safest general regulatory announcement category for this type of brief update, as it is not the presentation itself.
2017-03-08 English
Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barré syndrome (GBS)
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated February 16, 2017. It announces new pre-clinical data regarding the treatment potential of IdeS for Guillain-Barré syndrome (GBS) and mentions plans to begin a Phase II study. It also contains boilerplate information about the company and states, "This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act." This structure—a press release announcing scientific/clinical progress and regulatory obligations—is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a specific financial report category. Since this is a scientific/clinical update rather than a formal financial report (like 10-K or IR) or a management discussion (MDA), and it is an official announcement mandated by trading laws, the most appropriate general category for non-financial, mandatory corporate disclosures that don't fit elsewhere is Regulatory Filings (RNS). It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (ER/IR/10-K). Given the context of mandatory disclosure of material, non-financial news, RNS is the best fit.
2017-02-16 English
Nya prekliniska in vivo-data visar potentialen för IdeS behandling i Guillain-Barrés syndrom (GBS)
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESSMEDDELANDE" (Press Release) dated February 16, 2017. It announces new preclinical data regarding the IdeS treatment for Guillain-Barré syndrome (GBS) and mentions plans to initiate a Phase II study. This type of announcement, detailing scientific progress, clinical trial plans, and linking to a published scientific article, is characteristic of an early-stage corporate update, often related to R&D or clinical pipeline news. It is not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a transcript (CT). Since it is a general announcement of scientific/clinical progress that doesn't fit the specific categories like DIV, CAP, or MANG, and it is a formal communication from the company, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard corporate news releases, although it could also be argued as an Investor Presentation (IP) if it were a slide deck, but here it reads like a news announcement. Given the options, RNS is the most appropriate fallback for a press release detailing scientific findings and future plans that isn't a core financial report or a specific event announcement.
2017-02-16 Swedish
Audit Report / Information 2016
Audit Report / Information Classification · 95% confidence The document is titled "Bokslutskommuniké 2016" (Year-end report 2016) and contains a detailed "Ekonomisk översikt" (Financial overview) for the fourth quarter and the full year 2016, including key figures like Net Sales, Operating Result, and Earnings per Share for both 2016 and 2015. It also includes a CEO's statement reviewing the year's operations and future outlook. This structure—a comprehensive review of the full fiscal year's performance, including detailed financial tables and management discussion—is characteristic of an Annual Report or a year-end financial communication. Since the document is a 'Bokslutskommuniké' (Year-end report/Financial statement release) and provides comprehensive annual financial data, it aligns best with the definition of an Annual Report (10-K), although it might be a preliminary version or a local equivalent. Given the depth of financial data covering the entire year, 10-K is the most appropriate classification among the provided options for a full-year financial disclosure. FY 2016
2017-02-15 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Year-End Report 2016' and contains comprehensive financial data, including a CEO statement, business overview, pipeline details, and condensed financial statements for the full year and the fourth quarter. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year (or in this case, the year-end results which function as the final quarterly/interim reporting period). Q4 2016
2017-02-15 English
Hansa Medical announces successful completion of a Phase II clinical trial of IdeS in sensitized kidney patients
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated December 21, 2016. It announces the successful completion of a Phase II clinical trial for a drug called IdeS. This type of announcement, detailing clinical trial progress and results, is typically classified as an Earnings Release (ER) if it were quarterly results, but since this is a specific clinical/scientific milestone announcement, it fits best under the general category for significant corporate news that isn't a formal financial report or management change. Given the options, it is a significant corporate update. It is not a full Annual Report (10-K), Interim Report (IR), or a specific regulatory filing like DIRS or DIV. It is a press release announcing a major development. While 'ER' often covers earnings, it is also used for major operational news releases. However, since it is a specific announcement of a clinical trial result, and not a general earnings report, the most appropriate general category for non-standard, important corporate news that doesn't fit elsewhere is 'RNS' (Regulatory Filings/General Announcements), or potentially 'ER' if we interpret 'ER' broadly as 'Earnings/Results Release'. Given the context of a biopharma company announcing trial success, this is a key operational update. Since there is no specific 'Clinical Trial Update' code, and it is a formal announcement intended for the market, 'RNS' (Regulatory Filings/General Announcements) is the safest fallback for a press release that isn't a formal financial statement or management change. However, if we consider the intent to inform investors of a major operational milestone, 'ER' (Earnings Release) is often used broadly for major results announcements. Given the structure and content (a press release announcing a key milestone), 'RNS' is the most accurate fit as a general regulatory/corporate announcement that isn't a formal financial report.
2016-12-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.